After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Organogenesis Holdings Inc is listed on the NASDAQ in the Healthcare sector while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Organogenesis Holdings Inc is $649.79M. A total of 1.69 million shares were traded on the day, compared to an average of 1.42M shares.
In the most recent transaction, NUSSDORF GLENN H bought 251,001 shares of ORGO for 3.09 per share on May 14 ’25. After the transaction, the Director now owns 251,001 company shares. In a previous transaction on May 15 ’25, NUSSDORF GLENN H bought 107,494 shares at 2.99 per share. ORGO shares that Director owns now total 358,495.
Among the insiders who sold shares, NUSSDORF GLENN H disposed of 18,620 shares on Jun 10 ’25 at a per-share price of $3.56. This resulted in the Director holding 335,719 shares of ORGO after the transaction. In another insider transaction, NUSSDORF GLENN H sold 4,156 shares at $3.50 per share on Jun 09 ’25. Company shares held by the Director now total 354,339.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, ORGO has a high of $7.08 and a low of $2.61.
As of this writing, ORGO has an earnings estimate of $0.21 per share for the current quarter. EPS was calculated based on a consensus of 1.0 estimates, with a high estimate of $0.21 per share and a lower estimate of $0.21. The company reported an EPS of $0.07 in the last quarter
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. ORGO’s latest balance sheet shows that the firm has $113.93M in Cash & Short Term Investments as of fiscal 2021. There were $132.30M in debt and $82.70M in liabilities at the time. Its Book Value Per Share was $2.01, while its Total Shareholder’s Equity was $241.34M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ORGO is Buy with a score of 4.33.
